Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise

Phillip L. Palmbos, Maha H. Hussain

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

Metastatic prostate cancer remains a highly lethal disease with no curative therapeutic options. A significant subset of patients with prostate cancer harbor either germline or somatic mutations in DNA repair enzyme genes such as BRCA1, BRCA2, or ATM. Emerging data suggest that drugs that target poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) enzymes may represent a novel and effective means of treating tumors with these DNA repair defects, including prostate cancers. Here we will review the molecular mechanism of action of PARP inhibitors and discuss how they target tumor cells with faulty DNA repair functions and transcriptional controls. We will review emerging data for the utility of PARP inhibition in the management of metastatic prostate cancer. Finally, we will place PARP inhibitors within the framework of precision medicine-based care of patients with prostate cancer.

Original languageEnglish (US)
Pages (from-to)377-385
Number of pages9
JournalOncology (Williston Park, N.Y.)
Volume30
Issue number5
StatePublished - May 1 2016

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise'. Together they form a unique fingerprint.

Cite this